Incannex gets 180-day Nasdaq extension to April 20, 2026 for bid price compliance

Incannex Healthcare Inc.

Nasdaq granted Incannex until April 20, 2026 to maintain $1.00 closing bid for 10 consecutive days.
Extension follows Incannex meeting all other listing criteria and providing reverse stock split intent.
CEO notes two Phase 2 clinical data packages delivered in 2025 and strong cash position.
Company will monitor share price and take actions to regain compliance within the extension period.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.